The NMJ represents a crucial point of vulnerability across a range of neurological and neuromuscular conditions, where gene therapies are emerging as powerful therapeutic interventions (e.g., Zolgensma for SMA and Tofersen for SOD1-linked ALS patients).35 Here, SOD1 is linked to proximal spinal muscular atrophy.